Virax Biolabs Group Ltd. Class A stock analysis
Virax Biolabs Group Ltd. Class A (VRAX) Stock Price & Analysis
VRAX Stock Chart & Stats
- Day’s Range
- $0.29 - $0.46
- 52-Week Range
- $0.29 - $21.75
- Previous Close
- $0.43
- Volume
- N/A
- Average Volume (3M)
- 610.09K
- Market Cap
- $512.44K
- Enterprise Value
- -$2.07T
- Total Cash (Recent Filing)
- $6.52M
- Total Debt (Recent Filing)
- $414.39K
- Price to Earnings (P/E)
- ―
- Beta
- 2.19
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Virax Biolabs Group Ltd. Class A News
Virax Biolabs signs three new distributor agreements to build China sales
Virax Biolabs (VRAX) announced that, through its China subsidiary, Shanghai Xitu Consulting Co., Ltd., it has entered into non-exclusive distribution agreements with AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd.,
Virax Biolabs signs multi-country commercial agreement with Fosun Diagnostics
Virax Biolabs (VRAX) Group announced that its wholly owned subsidiary, Virax Biolabs Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company’s ImmuneSelect research-use
VRAX FAQ
What was Virax Biolabs Group Ltd. Class A’s price range in the past 12 months?
What is Virax Biolabs Group Ltd. Class A’s market cap?
When is Virax Biolabs Group Ltd. Class A’s upcoming earnings report date?
How were Virax Biolabs Group Ltd. Class A’s earnings last quarter?
Is Virax Biolabs Group Ltd. Class A overvalued?
Does Virax Biolabs Group Ltd. Class A pay dividends?
What is Virax Biolabs Group Ltd. Class A’s EPS estimate?
How many shares outstanding does Virax Biolabs Group Ltd. Class A have?
What happened to Virax Biolabs Group Ltd. Class A’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Virax Biolabs Group Ltd. Class A?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Foster
- Employees
- 26
- Website
- viraxbiolabs.com
- Address
- BioCity Glasgow, Lanarkshire, SC, ML1 5UH, GB
Virax Biolabs Group Ltd. Class A (VRAX) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |












